MedTrace Logo

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

NCT02463994 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-02-08

No results posted yet for this study

Summary

The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is known to block the effects of the body's immune system in attacking the cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if prior treatment with radiation will allow improved recognition of the cancer by the body's immune cells in the presence of MPDL3280A.

Conditions

Interventions

DRUG

MPDL3280A

Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.

RADIATION

Hypofractionated Radiotherapy

Hypofractionated Image-Guided Radiotherapy (HIGRT)

Sponsors & Collaborators

Principal Investigators

  • Nithya Ramnath, M.D. · University of Michigan Rogel Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-11-07
Completion
2018-11-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02463994 on ClinicalTrials.gov